A novel telomerase template antagonist (GRN163) as a potential anticancer agent

Cancer Research

Volumn 63, Issue 14, 2003, Pages 3931-3939

  Asai, Akira ^a   Oshima, Yuko ^a   Yamamoto, Yoshihiro ^a   Uochi, Taka aki ^a   Kusaka, Hideaki ^a   Akinaga, Shiro ^a   Yamashita, Yoshinori ^a   Pongracz, Krisztina ^b   Pruzan, Ronald ^b   Wunder, Ellen ^b   Piatyszek, Mieczyslaw ^b   Li, Shihong ^b   Chin, Allison C ^b   Harley, Calvin B ^b   Gryaznov, Sergei ^b  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b GERON CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GRN 163; PHOSPHORAMIDIC ACID DERIVATIVE; PROTEIN SUBUNIT; RNA; TELOMERASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL AGING; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; IC 50; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TELOMERE; TUMOR XENOGRAFT;

AMIDES; BIOLOGICAL AVAILABILITY; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; OLIGONUCLEOTIDES; PHOSPHORIC ACIDS; RNA; TELOMERASE;

EID: 0042674370     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Feng, J., Funk, W. D., Wang, S-S., Weinrich, S. L., Avilion, A. A., Chiu, C-P., Adams, R. R., Chang, E., Yu, J., Le, S., West, M. D., Harley, C. B., Andrews, W. H., Greider, C. W., and Villeponteau, B. The RNA component of human telomerase. Science (Wash. DC), 269: 1236-1241, 1995.
2. Nakamura, T. M., Morin, G. B., Chapman, K. B., Weinrich, S. L., Andrews, W. H., Lingner, J., Harley, C. B., and Cech, T. R. Telomerase catalytic subunit homologs from fission yeast and human. Science (Wash. DC), 277: 911-912, 1997.
3. Kondo, S., Kondo, Y., Li, G., Silverman, R. H., and Cowell, J. K. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene, 16: 3323-3330, 1998.
4. Ludwig, A., Saretzki, G., Holm, P. S., Tiemann, F., Lorenz, M., Emrich, T., Harley, C. B., and von Zglinicki, T. Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res., 61: 3053-3061, 2001.
5. Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., and Shay, J. W. Specific association of human telomerase activity with immortal cells and cancer. Science (Wash. DC), 266: 2011-2015, 1994.
6. Harley, C. B. Telomerase is not an oncogene. Oncogene, 21: 494-502, 2002.
7. Counter, C. M., Hirte, H. W., Bacchetti, S., and Harley, C. B. Telomerase activity in human ovarian carcinoma. Proc. Natl. Acad. Sci. USA, 91: 2900-2904, 1994.
8. Ohyashiki, J. H., Sashida, G., Tauchi, T., and Ohyashiki, K. Telomeres and telomerase in hematologic neoplasia. Oncogene, 21: 680-687, 2002.
9. Naasani, I., Seimiya, H., and Tsuruo, T. Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochem. Biophys. Res. Comm, 249: 391-396, 1998.
10. Damm, K., Hemmann, U., Garin-Chesa, P., Hauel, N., Kauffmann, I., Priepke, H., Niestroj, C., Daiber, C., Enenkel, B., and Guilliard, B. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J., 20: 6958-6968, 2001.
11. Naasani, I., Seimiya, H., Yamori, T., and Tsuruo, T. F. J.5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res., 59: 4004-4011, 1999.
12. Hisatake, J., Kubota, T., Hisatake, Y., Uskokovic, M., Tomoyasu, S., and Koeffler, H. P. 5, 6- trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells. Cancer Res, 59: 4023-4029, 1999.
13. Neidle, S., Harrison, R. J., Reszka, A. P., and Read, M. A. Structure-activity relationships among guanine-quadruplex telomerase inhibitors. Pharmacol. Ther., 85: 133-139, 2000.
14. Hurley, L. H., Wheelhouse, R. T., Sun, D., Kerwin, S. M., Salazar, M., Fedoroff, O. Yu Han, F. X., Han, H., Izbicka, E., and Von Hoff, D. D. G-quadruplexes as targets for drug design. Pharmacol. Ther., 85: 141-158, 2000.
15. Hahn, W. C., Stewart, S. A., Brooks, M. W., York, S. G., Eaton, E., Kurachi, A., Beijersbergen, R. L., Knoll, J. H. M., Meyerson, M., and Weinberg, R. A. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med., 5: 1164-1170, 1999.
16. Glukhov, A. I., Zimnik, O. V., Gordeev, S. A., and Severin, S. E. Inhibition of telomerase activity of melanoma cells in vitro by antisense oligonucleotides. Biochem. Biophys. Res. Comm., 248: 368-371, 1998.
17. Mukai, S., Kondo, Y., Koga, S., Komata, T., Barna, B. P., and Kondo, S. 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. Cancer Res., 60: 4461-4467, 2000.
18. Norton, J. C., Piatyszek, M. A., Wright, W. E., Shay, J. W., and Corey, D. R. Inhibition of human telomerase activity by peptide nucleic acids. Nat. Biotechnol., 14: 615-619, 1996.
19. Matthes, E., and Lehmann, C. Telomerase protein rather than its RNA is the target of phosphorothioate-modified oligonucleotides. Nucleic Acids Res., 27: 1152-1158, 1999.
20. Pitts, A. E., and Corey, D. R. Inhibition of human telomerase by 2′-O-methyl-RNA. Proc. Natl. Acad. Sci. USA, 95: 11549-11554, 1998.
21. Elayadi, A. N., Demieville, A., Wancewicz, E. V., Monia, B. P., and Corey, D. R. Inhibition of telomerase by 2′-O-(2-methoxyethyl) RNA oligomers: effect of length, phosphorothioate substitution and time inside cells. Nucleic Acids Res., 29: 1683-1689, 2001.
22. Wan, M. S. K., Fell, P. L., and Akhtar, S. Synthetic 2′-O-methyl-modified hammerhead ribozymes targeted to the RNA component of telomerase as sequence-specific inhibitors of telomerase activity. Antisense Nucleic Acid Drug Dev., 8: 309-317, 1998.
23. Kondo, Y., Komata, T., and Kondo, S. Combination therapy of 2-5A antisense against telomerase RNA and cisplatin for malignant gliomas. Int. J. Oncol., 18: 1287-1292, 2001.
24. Herbert, B-S., Pitts, A. E., Baker, S. I., Hamilton, S. E., Wright, W. E., Shay, J. W., and Corey, D. R. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl. Acad. Sci. USA, 96: 14276-14281, 1999.
25. Gryaznov, S., Pongracz, K., Matray, T., Schultz, R., Pruzan, R., Aimi, J., Chin, A., Harley, C., Shea-Herbert, B., Shay, J., Oshima, Y., Asai, A., and Amashita, Y. Telomerase inhibitors-oligonucleotide phosphoramidates as potential therapeutic agents. Nucleosides Nucleotides Nucleic Acids, 20: 401-410, 2001.
26. Shea-Herbert, B., Pongracz, K., Shay, J., and Gryaznov, S. Oligonucleotide N3′→P5′ phosphoramidates as efficient telomerase inhibitors. Oncogene, 21: 638-642, 2002.
27. Sharma, H. W., Hsiao, R., and Narayanan, R. Telomerase as a potential molecular target to study G-quartet phosphorothioates. Antisense Nucleic Acid Drug Dev., 6: 3-7, 1996.
28. Boulme, F., Freund, F., Moreau, S., Nielsen, P., Gryaznov, S., Toulme, J-J., and Litvak, S. Modified (PNA, 2′-O-methyl and phosphoramidate) anti-TAR antisense oligonucleotides as strong and specific inhibitors of in vitro HIV-1 reverse transcription. Nucleic Acids Res., 26: 5492-5500, 1998.
29. Pongracz, K., and Gryaznov, S. Oligonucleotide N3′→P5′ thio-phosphoramidates: synthesis and properties. Tetrahedron Lett., 40: 7661-7664, 1999.
30. McCurdy, S. N., Nelson, J. S., Hirschbein, B. L., and Fearon, K. L. An improved method for the synthesis of N3′→P5′ phosphoramidates oligonucleotides. Tetrahedron Lett. 38: 207-210, 1997.
31. Pruzan, R., Pongracz, K., Gietzen, K., Wallweber, G., and Gryaznov, S. Allosteric inhibitors of telomerase: oligonucleotide N3′→P5′ phosphoramidates. Nucleic Acids Res., 30: 559-568, 2002.
32. Chin, A. C., Tolman, R. L., Nguyen, M. Q., and Holcomb, R. Substituted Indole Compounds and Methods of Their Use. United States Patent #6, 372, 742 B1 issued April 16, 2002.
33. Counter, C. M., Avilion, A. A., LeFeuvre, C. E., Stewart, N. G., Greider, C. W., Harley, C. B., and Bacchetti, S. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J., 5: 1921-1929, 1992.
34. Wenz, C., Enenkel, B., Amacker, M., Kelleher, C., Damm, K., and Lingner, J. Human telomerase contains two cooperating telomerase RNA molecules. EMBO J. 20: 3526-3534, 2001.
35. Heidenreich, O., Gryaznov, S., and Nerenberg, M. RNase H-independent antisense activity of oligonucleotide N3′-P5′ phosphoramidates. Nucleic Acids Res., 25: 776-780, 1997.
36. Rudolph, K. L., Chang, S., Lee, H. W., Blasco, M., Goettlieb, G. J., Greider, C. W., and DePinho, R. A. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell, 96: 701-712, 1999.
37. Morris, M. C., Chaloin, L., Mery, J., Hietz, F., and Divita, G. A. novel potent strategy for gene delivery using a single peptide vector as a carrier. Nucleic Acids Res., 27: 3510-3517, 1999.